Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy in PD-L1-positive metastatic squamous NSCLC
NL-OMON61110Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rilvegostomig, pembrolizumab, carboplatin in Pulmonary squamous cell carcinoma, non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
Pulmonary squamous cell carcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61110.